Vuzix Corporation (NASDAQ: VUZI) — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; quarterly data below includes the fourth quarter. Vuzix designs, manufactures and sells augmented-reality smart glasses, waveguide optics, display engines and related software/services, primarily for enterprise, medical, industrial and defense markets.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $12.13 million | $11.84 million |
| Gross profit (loss) | $(2.63) million; (22)% margin | $1.48 million; 13% margin |
| Operating loss | $(52.30) million | $(42.23) million |
| Net loss | $(50.15) million; $(0.79) per share | $(40.76) million; $(0.64) per share |
| Cash used in operations | $(26.28) million | $(24.52) million |
| Cash used in investing | $(19.28) million | $(21.17) million |
- FY2023 revenue rose 2%; product sales increased 2% and engineering-services sales increased 3%. Smart-glasses revenue, including higher M400 unit sales, was cited as a product-sales driver.
- Cash and cash equivalents were $26.56 million at year-end, down from $72.56 million. Working capital was $36.28 million, versus $75.35 million a year earlier. The company reported no current or long-term debt; outstanding contractual commitments included $1.0 million of licensing fees at year-end.
- Fourth-quarter 2023 revenue was $1.07 million, gross loss $4.25 million, net loss $19.88 million and loss per share $0.32. Quarterly figures are unaudited.
Material changes and unusual items
- Gross margin swung from positive 13% to negative 22%, principally amid a $4.36 million FY2023 inventory-obsolescence charge. The year-end inventory reserve was $5.78 million, including a $2.70 million provision for excess components linked to expected product-model transitions.
- Operating expenses increased to $49.67 million from $43.72 million. Selling and marketing rose 57% to $12.71 million, including a $1.57 million bad-debt reserve; research and development declined 3% to $12.34 million; general and administrative expense declined 12% to $18.59 million.
- Vuzix recorded a $2.14 million impairment of Moviynt goodwill and intangible assets, citing slower-than-expected revenue growth. Depreciation and amortization increased, largely reflecting amortization of the Atomistic technology license.
- Vuzix paid $10.5 million toward Atomistic license commitments and invested $2.5 million in Atomistic preferred shares during 2023. The filing reports $32.5 million in cumulative cash paid to Atomistic over the prior two fiscal years.
Outlook, risks and contingencies
- Going concern: Recurring losses and operating cash outflows raise substantial doubt about the company’s ability to continue as a going concern; management’s plans have not fully alleviated that doubt. Management estimated liquidity could fund operations at least through the second quarter of 2025, subject to forecasts and execution.
- Management cited approximately $8 million of planned 2024 cash operating-expense reductions, completed waveguide-facility expansion, inventory sales, lower discretionary spending and anticipated waveguide/OEM contribution. A voluntary payroll-reduction program was expected to save $1.2 million. These are plans and expectations, not assured results.
- In early 2024, Vuzix entered an at-the-market agreement allowing up to $50 million of common-stock sales. Management also disclosed tentative agreement to provide Atomistic a further $5 million in 2024 to extend the exclusive technology license through December 31, 2025. Additional milestone-related share issuances may dilute shareholders.
- Key risks include sustained losses and cash burn; uncertain customer demand and cancellable orders; competition and long OEM qualification cycles; inventory obsolescence; dependence on third-party component suppliers; and the technical, funding and license-renewal risks associated with Atomistic microLED development.
- Management found disclosure controls and internal control over financial reporting ineffective at year-end due to a material weakness: a Q4 impairment-triggering event was not identified timely. Management described remediation steps, including additional accounting/valuation expertise and Audit Committee reporting.
- The independent auditor issued an unqualified opinion on the financial statements while highlighting the going-concern uncertainty. The auditor was not engaged to provide an opinion on internal-control effectiveness.
Most important facts for investors to verify
- Cash runway against operating cash burn, planned expense cuts, any further financing, and the proposed $50 million ATM capacity.
- Whether the $5 million Atomistic license extension is finalized, its terms, remaining milestones and the technology’s development/commercialization progress.
- Waveguide production yields, OEM customer commitments and conversion of development projects into meaningful recurring or volume revenue.
- Inventory sell-through and the adequacy of obsolescence reserves, plus collection of receivables following the $1.57 million bad-debt reserve and disclosed customer concentration.
- Progress remediating the material weakness and the potential dilution from equity financing, employee awards and Atomistic milestone shares.